Examine personalized NK cell therapy’s international rollout and its cross-disease potential alongside manufacturing and regulatory implications.
Key Takeaways
- NKGen will present its lead investigational therapy troculeucel at the 2026 BIOCHINA forum
- Troculeucel is an autologous NK cell therapy expanded ex vivo and returned to patients
- Company expanded its Phase 2 Alzheimer’s trial to additional U.S